Navigation Links
Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
Date:4/15/2011

SAN DIEGO, April 15, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from a new analysis of an ongoing, long-term research study of the investigational drug metreleptin, an analog of the human hormone leptin, for the treatment of lipodystrophy. The study is being conducted by investigators from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH). Results from the analysis will be presented by Christian Weyer, M.D., senior vice president, research and development, Amylin Pharmaceuticals, at a late-breaking oral session on Sunday, April 17 at 7:55 a.m. PT at the 20th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists (AACE) in San Diego.

In the study, which has been ongoing for more than 10 years, researchers at the NIH are examining the effect of metreleptin on several metabolic abnormalities, including diabetes and hypertriglyceridemia (high levels of triglycerides in the bloodstream), in patients with rare inherited or acquired forms of lipodystrophy. Treatment with metreleptin resulted in robust reductions from baseline in both A1C and triglycerides. (A1C is a measure of average blood sugar over three months; triglycerides are the major form of fat stored in the body.) These improvements were apparent at four months and generally sustained for up to several years of treatment.

"Patients with rare forms of lipodystrophy are often affected by the disease early in life, are at high risk of acute and chronic complications and, currently, have very limited therapeutic options," said Dr. Weyer. "The results of our analysis reaffirm the potential of metreleptin as an important advance for people living with this chronic and often debilitating metabolic disease. We continue to work diligently toward bringing this potential
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)...  Decision Resources, one of the world,s leading ... issues, finds that, for the treatment of rheumatoid ... rheumatologists cite a therapy,s induction of remission as ... prescribing decisions. Over 60 percent and 70 percent ... percentage of patients achieving remission at six months ...
(Date:6/19/2013)... JOSE, Calif. , June 19, 2013 BD ... BDX ), a leading global medical technology company, ... Cell Analyzer , the latest in its line of high-performance ... Cell Analyzer delivers high-performance multicolor analysis with the most compact ... X 73.7 cm) and a height of 30" (76.2 cm). ...
(Date:6/19/2013)... , June 19, 2013 /PRNewswire-iReach/ -- In ... new specialty pharmaceutical company dedicated to advancing ... injectable and sustained release drug therapies in ... needs, today announced the acquisition of Enzon ... platform and associated product pipeline. Acquisition of ...
Breaking Medicine Technology:U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis 2New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4
(Date:6/19/2013)... (PRWEB) June 19, 2013 DiscountFurnaceFilter.com, the number ... to offer the 5-2-1 Compressor Saver kit at an exceptional ... Start Kit) aids the air conditioning unit during start up, ... prevent air compressor or unit burn out. , The ... so the air conditioner uses less power to start and ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Alternatives, a ... some patients to quit using drugs while allowing them ... Jaffe, the founders of Alternatives, believe that abstinence-only approaches ... they enter treatment and that this approach hurts instead ... people in the United States need treatment for addiction ...
(Date:6/19/2013)... 19, 2013 Kansas City will host its first ... Street Day . A section of Main Street in the midtown ... afternoon of the event. The Main Street Corridor Development ... will help Kansas City join the ranks of dozens of cities ... tool to foster community vibrancy and active lifestyles. , “Ciclovia is ...
(Date:6/19/2013)... 19, 2013 Many trying-to-conceive couples ... medically necessary, according to a recent study ... Journal. The results of this research confirm what ... a decade – that trying-to-conceive women would benefit ... healthy body weight. Fairhaven Health is a leading ...
(Date:6/19/2013)... In 2011, the value of the Serbian ... drugs form the largest sector, accounting for nearly one ... is a significant contributor to the local economy; it ... 50% of the total domestic chemical industry output fall ... and Zdravlje Actavis are key participants in the Serbian ...
Breaking Medicine News(10 mins):Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 2Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4Health News:Serbian Pharmaceutical Market Scrutinized by CUBE in Topical Report Now Available at MarketPublishers.com 2
... Danaher Corporation (NYSE: DHR ) announced that President ... presenting at the Morgan Stanley Global Industrials Conference in New ... EDT. The audio will be simultaneously webcast on www.danaher.com. A ... following the presentation. , , Danaher Corporation ...
... , THE WOODLANDS, Texas, Aug. 26 ... providing a service called Custom Separation Synthesis(TM) to customers primarily ... separation problems for which they would like more economically viable ... alternative separation schemes that are lower in capital and operating ...
... Pa., Aug. 26 Environmental Tectonics Corporation,s (OTC Bulletin ... a product division in ETC,s Controls Systems Group, has ... installation of the first BARA-MED((R)) computerized monoplace hyperbaric chamber ... International is a "turn-key" supplier, providing all the necessary ...
... , , , ... a leading provider of kidney care services for those diagnosed with ... announced that it will present three abstracts at the 3rd North ... on August 27-29 in Vancouver, British Columbia. , , ...
... ... , ... (Vocus) August 26, 2009 -- Bariatric Advantage , a Division of Catalina Lifesciences, ... the many bariatric surgical programs that are helping less fortunate patients "RECOVER" from obesity ...
... ... WAVE (Whole-Body Advanced Vibration Exercise) is pleased to announce that the ... Physiomed, a multi location health care provider network with comprehensive rehabilitation ... experience WAVE,s revolutionary technology in the Physiomed facilities, with the implementation ...
Cached Medicine News:Health News:Trans Ionics Announces New Service - Custom Separation Synthesis (CSS)(TM) 2Health News:Environmental Tectonics Corporation's BioMedical Systems Division Announces First BARA-MED(R) Monoplace Hyperbaric Chamber Sale in Romania 2Health News:Environmental Tectonics Corporation's BioMedical Systems Division Announces First BARA-MED(R) Monoplace Hyperbaric Chamber Sale in Romania 3Health News:Environmental Tectonics Corporation's BioMedical Systems Division Announces First BARA-MED(R) Monoplace Hyperbaric Chamber Sale in Romania 4Health News:DaVita to Present Three Abstracts for the International Society for Peritoneal Dialysis 2Health News:Bariatric Advantage Launches Highly Anticipated RECOVER Program Through Obesity Action Coalition 2Health News:WAVE Begins Shipment of Vibration Technology to Physiomed Franchises 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: